| pubmed-article:11679189 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11679189 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:11679189 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:11679189 | lifeskim:mentions | umls-concept:C0393078 | lld:lifeskim |
| pubmed-article:11679189 | lifeskim:mentions | umls-concept:C1446539 | lld:lifeskim |
| pubmed-article:11679189 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:11679189 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11679189 | pubmed:dateCreated | 2001-10-26 | lld:pubmed |
| pubmed-article:11679189 | pubmed:abstractText | Although 5-FU administered as a single agent in different intravenous bolus schedules has been shown to have minimal activity in non-small cell lung cancer (NSCLC), several lines of experimental evidence suggest that 5-FU in combination regimens may be synergistic with the 'anchor' drug of the combination. Moreover, the recent availability of oral formulations of 5-FU together with the ability to modulate the anabolic and catabolic metabolism of 5-FU with leucovorin and dihydropyrimidine dehydrogenase (DPD) inhibitors, respectively, may provide a substantial improvement in the ease of administration and the efficacy of fluoropyrimidine therapy. Several oral fluoropyrimidines are under investigation. Orzel [UFT (uracil:tegafur) plus oral leucovorin] is the first oral DPD-inhibitory fluoropyrimidine. Orzel administered daily achieves similar concentrations of 5-FU obtained with continuous-infusion 5-FU. This paper reviews the clinical experience with UFT and Orzel in the treatment of NSCLC. | lld:pubmed |
| pubmed-article:11679189 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11679189 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11679189 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11679189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11679189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11679189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11679189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11679189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11679189 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11679189 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11679189 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:11679189 | pubmed:issn | 0169-5002 | lld:pubmed |
| pubmed-article:11679189 | pubmed:author | pubmed-author:LangerC JCJ | lld:pubmed |
| pubmed-article:11679189 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11679189 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:11679189 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11679189 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11679189 | pubmed:pagination | 297-303 | lld:pubmed |
| pubmed-article:11679189 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:meshHeading | pubmed-meshheading:11679189... | lld:pubmed |
| pubmed-article:11679189 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11679189 | pubmed:articleTitle | The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer. | lld:pubmed |
| pubmed-article:11679189 | pubmed:affiliation | Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111-2412, USA. cj_langer@fccc.edu | lld:pubmed |
| pubmed-article:11679189 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11679189 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:11679189 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
